ArticleJournal of the Endocrine Society2026
The impact of statins on aldosterone production in healthy adults: a randomized controlled study.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Statins lower atherosclerotic cholesterol, but the cardiovascular benefit from treatment may extend beyond lipid management. Our group previously described in an observational study that individuals on statin therapy had 33% lower aldosterone (ALDO) than individuals not on statins, and this effect was greater in individuals taking a lipophilic statin (eg, simvastatin) than a hydrophilic statin (eg, pravastatin). Further, studies in isolated rodent adrenal zona glomerulosa cells demonstrated that statins lowered ALDO, and again lipophilic statins had a greater effect. We, therefore, tested the hypothesis that treatment with simvastatin would result in lower than treatment with pravastatin or placebo in a randomized controlled trial. Methods: We conducted a 12-week, double-blind, randomized, placebo-controlled clinical trial among healthy adults with low-density lipoprotein cholesterol (LDL-C) > 70 mg/dL. Participants were randomized 1:1:1 to placebo, simvastatin 20 mg, or pravastatin 40 mg, stratified by sex. The study medication dose was doubled at Week 6 if the LDL-C decreased by less than 35% from screening values. We performed ALDO assessments at pretreatment, Week 6, and Week 12 posttreatment after 5 days on a controlled low-sodium diet. Results: Multivariate regression analysis controlling for sex, age, race, BMI, and pretreatment angiotensin II (AngII)-stimulated ALDO showed no significant differences in 12-week posttreatment AngII-stimulated ALDO between placebo and simvastatin ( Conclusion: Among healthy individuals on a low-sodium diet, 12-week treatment with simvastatin or pravastatin did not alter ALDO responsiveness to AngII.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.